All articles
Ozempic Feet: What It Means and When to Call a Provider
Reading time:
7 min
Get expert guidance and a personalized care plan designed around you.
Loose Skin and More Visible Veins
When the fat underneath shrinks, the skin above it does not always keep up. On the feet, that looks like slight looseness across the top of the foot, and as tendons, bones, and veins sitting closer to the surface than they did before.
This is a cosmetic change rather than a structural one, and it tracks the same pattern people notice in the face and hands. If the facial version is what brought you here, Ozempic face covers that separately, and the underlying change is similar.
Shoe Size and Fit
Plenty of people find their usual shoes fit differently after substantial weight loss. Reduced padding and reduced swelling both contribute, and the effect shows up as width more often than length.
There is not much formal research on shoe sizing specifically, so this rests largely on clinical observation and patient report rather than trial data. What follows is practical: footwear that fit comfortably at a higher weight may need reassessing, and cushioning matters more than it used to.
Nerve Symptoms
This is the part the podiatry blogs tend to miss, and it is the most clinically serious. A 2026 case series (3) documented weakness lifting the front of the foot, which doctors call peroneal nerve palsy, in two patients who had lost weight on tirzepatide.
The mechanism the authors propose is mechanical rather than chemical. The nerve runs close to the surface at the outside of the knee, where it is normally cushioned by fat. Where that padding thins, the authors suggest that ordinary habits such as sitting with your legs crossed can compress the nerve, though two cases point to a plausible mechanism rather than an established one. In both reported cases the weakness resolved over three to four months with behavioral changes and physical therapy (3).
Numbness, tingling, burning, or difficulty lifting your foot are not cosmetic complaints, and they deserve clinical assessment rather than a new pair of insoles.
Ozempic's Approved Use and Why the Name is Misleading
Semaglutide is sold under more than one brand name, with different approved uses attached to each:
Ozempic: approved for glycemic control in type 2 diabetes, with additional cardiovascular and kidney indications (8).
Wegovy: the semaglutide brand approved for chronic weight management (9).
So a person searching "Ozempic feet" may well be taking a different medication entirely. Tirzepatide, the active ingredient in Zepbound and Mounjaro, is reported to produce similar body composition effects, and the case series above involved tirzepatide rather than semaglutide (3). For more on the naming, see semaglutide versus Ozempic and Ozempic dosing.
Who Should Not Take Semaglutide
Semaglutide is not appropriate for everyone, whatever the brand. The prescribing information (8) describes people who should avoid it. This is not a complete list, and only a licensed provider reviewing your full history can determine whether a medication is appropriate for you.
Thyroid cancer history: anyone with a personal or family history of medullary thyroid cancer should avoid it.
MEN 2: the endocrine condition multiple endocrine neoplasia syndrome type 2 also rules it out.
A prior reaction: anyone who has had a serious allergic reaction to semaglutide should not take it, and pregnancy is a further reason a provider would rule it out.
Lean Tissue is a Real Share of the Loss
Here is the part that makes the foot changes make sense. Weight loss on these medications is not purely fat, and reviews of body composition during GLP-1 treatment report that lean soft tissue makes up a meaningful share of the total lost (5,6).
One of those reviews makes a point worth keeping in view, which is that caloric restriction on its own produces comparable lean mass loss, so this is not something distinctive to GLP-1 medications (6). Fat pads and the padding around nerves are part of what comes off, which is the connection between a number on a scale and a change in how your feet feel.
None of that means the medications are doing something wrong. It means weight loss is not selective, and the tissue you would rather keep needs deliberate protection. Individual results are not guaranteed and may vary from person to person.
Protecting Muscle and Padding in Four Steps
Body composition is the one part of this a person can influence while treatment continues. A 2024 review (5) examined mitigation strategies alongside the losses themselves, and a three-patient case series has since reported that lean soft tissue can be preserved where protein and resistance training are deliberate (4).
Ask your provider about protein intake. A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (10) suggests considering 1.2 to 1.6 grams of protein per kilogram of body weight when starting GLP-1 therapy, particularly alongside calorie restriction, while noting that no consensus exists on whether to base that target on actual, adjusted, or ideal body weight.
Discuss kidney health with your provider first. Protein targets need individual assessment if you have kidney disease, so these are questions for your provider rather than numbers to act on alone.
Add resistance training. It appears alongside protein in that literature rather than instead of it, so the two work together (7,10).
Track it rather than guessing. Monitoring is what makes body composition visible over time, and which labs to monitor covers what usually gets checked.
These are general educational points rather than a treatment plan, and they are not a substitute for advice from your own provider.
These findings come from studies of FDA-approved semaglutide and tirzepatide products. If you're prescribed a compounded version of these medications, talk to your provider about how that may differ.
Check your eligibility to have a licensed provider review your history and plan.
Foot Symptoms That Need a Provider
Some of this is cosmetic and some is not, and the difference matters. Aching after a long walk is a different conversation from numbness that does not resolve.
Contact your provider about numbness or tingling that persists, burning pain, weakness lifting your foot, a foot that catches or slaps when you walk, or pain that stops you walking normally. Any open sore or wound on the foot needs prompt attention, and that is more urgent again if you have diabetes, because reduced sensation can hide an injury until it is advanced.
Seek same-day care for sudden severe pain, a foot that is cold, pale, or blue, or rapid one-sided swelling, since those can point to circulation problems rather than padding. Your prescriber decides whether treatment continues or changes, so bring the symptoms to them rather than adjusting anything yourself.
The Bottom Line
"Ozempic feet" describes real changes, but it is a media label rather than a diagnosis, and the research underneath it concerns rapid weight loss rather than one brand. The best-documented piece is fat pad thinning, which published reviews link to higher pressure on the bones of the foot (1), studied in diabetes rather than after weight loss.
The share of GLP-1 weight loss that comes from lean tissue rather than fat (5,6) is what ties the scale to the symptom. The 2026 nerve case series (3) is the reminder that some foot and leg complaints are clinical rather than cosmetic.
What a provider evaluates is your symptoms, your rate of weight loss, your protein intake and activity, and whether anything about your treatment needs revisiting. You can also browse weight loss treatment and the common questions.
These findings come from studies of FDA-approved semaglutide and tirzepatide products. If you're prescribed a compounded version of these medications, talk to your provider about how that may differ.
Check your eligibility to talk to a provider about what you are noticing.
FAQs
Is Ozempic feet a real side effect?
It is not listed as a side effect in the prescribing information (8), and the term came from media coverage rather than from a trial. The underlying changes are real, though, and they follow substantial fat loss rather than one specific medication. Fat pad thinning has the clearest research behind it (1).
Will my feet go back to normal if I stop?
There is no good trial evidence either way, so nobody can tell you reliably. Fat distribution does change with weight regain, but that is not a treatment plan. Whether your treatment continues is a decision for your prescriber rather than something to change alone.
Why do my shoes not fit anymore?
Reduced padding and reduced swelling both change how a shoe sits, and width tends to shift before length. This rests on clinical observation rather than trial data. Footwear with more cushioning is worth raising with a podiatrist.
Does this happen with tirzepatide too?
The nerve case series discussed above involved tirzepatide rather than semaglutide (3), so these reports are not confined to one ingredient. Changes in body composition are described across GLP-1 and dual GLP-1 plus GIP medications, which is part of why a nickname attached to a single brand name is misleading.
References
Dalal S, Widgerow AD, Evans GRD. The plantar fat pad and the diabetic foot, a review. International Wound Journal. 2015;12(6):636-40. PMID 24131727. https://pmc.ncbi.nlm.nih.gov/articles/PMC7950511/
What do we actually know about a common cause of plantar heel pain? A scoping review of heel fat pad syndrome. Journal of Foot and Ankle Research. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9380282/
Weight Drop-Foot Drop: A Case Series of Peroneal Nerve Palsy from Leg Crossing after Tirzepatide-Mediated Weight Loss. Case Reports in Neurology. 2026;18(1):364-369. https://pmc.ncbi.nlm.nih.gov/articles/PMC13412237/
Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. SAGE Open Medical Case Reports. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12536186/
Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, Obesity and Metabolism. 2024. PMID 38937282. https://pubmed.ncbi.nlm.nih.gov/38937282/
Mocciaro G, et al. GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction. BMJ Nutrition, Prevention & Health. 2025;8(1):e001206. DOI 10.1136/bmjnph-2025-001206. PMID 40771503. https://pmc.ncbi.nlm.nih.gov/articles/PMC12322565/
Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. Metabolites. 2026;16(6):364. PMID 42346344. https://pubmed.ncbi.nlm.nih.gov/42346344/
Ozempic (semaglutide) injection, prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf Accessed September 2026.
Wegovy (semaglutide) injection, prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf Accessed September 2026.
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12304835/
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan. Semaglutide and tirzepatide require a written prescription from a licensed provider. Speak with a provider to determine if a GLP-1 medication is appropriate for you. Ozempic is FDA-approved for type 2 diabetes and is prescribed off-label for weight loss, so the FDA has not evaluated it for that use, while Wegovy is FDA-approved for chronic weight management. Individual results are not guaranteed and may vary from person to person. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. These names are used for identification only and do not imply any affiliation with, or endorsement by, their owners. All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. provides administrative and technology services to affiliated medical practices it supports, and does not provide any professional medical services itself.
More articles
Read next
For iOS & Android
